0001562180-24-000785.txt : 20240129
0001562180-24-000785.hdr.sgml : 20240129
20240129175406
ACCESSION NUMBER: 0001562180-24-000785
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240126
FILED AS OF DATE: 20240129
DATE AS OF CHANGE: 20240129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jones David Scott
CENTRAL INDEX KEY: 0001779458
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 24575189
MAIL ADDRESS:
STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC.,
STREET 2: 480 PLEASANT STREET, SUITE A210
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-01-26
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001779458
Jones David Scott
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
false
true
false
false
SVP & Chief Commercial Officer
true
Common Stock
2024-01-26
4
M
false
9604.00
12.90
A
47566.00
D
Common Stock
2024-01-26
4
M
false
16413.00
3.26
A
63979.00
D
Common Stock
2024-01-26
4
S
false
16413.00
25.4465
D
47566.00
D
Common Stock
2024-01-26
4
S
false
9604.00
25.2725
D
37962.00
D
Stock Option (Right to Buy)
12.90
2024-01-26
4
M
false
9604.00
0.00
D
2030-02-28
Common Stock
9604.00
8721.00
D
Stock Option (Right to Buy)
3.26
2024-01-26
4
M
false
16413.00
0.00
D
2033-01-05
Common Stock
16413.00
68742.00
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
/s/ Ron Honig, Attorney-in-Fact
2024-01-29